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Abstract
Nearly 30 years ago, we reported on a concept now known as Tissue Engineering. Here, we report 
on some of the advances in this now thriving area of research. In particular, significant advances 
in tissue engineering of skin, liver, spinal cord, blood vessels, and other areas are discussed.
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Introduction
Nearly 30 years ago, we wrote a paper entitled “Selective cell transplantation using 
bioabsorbable artificial polymers as matrices [1].” In this paper we described attaching cell 
preparations to bioerodable artificial polymers in cell culture and then implanting this 
polymer-cell scaffold into animals. Using techniques of cell harvest, single cells and clusters 
of fetal and adult rat and mouse hepatocytes, pancreatic islet cells and small intestinal cells 
were seeded onto a number of different biodegradable polymers. Sixty-five fetuses and 14 
adult animals served as donors. One hundred fifteen polymer scaffolds were implanted into 
70 recipient animals: 66 seeded with hepatocytes, 23 with intestinal cells and clusters and 26 
with pancreatic islet preparations. The cells remained viable in culture and, in the case of 
fetal intestine and fetal hepatocytes, appeared to proliferate while on the polymer. After four 
days in culture the cell-polymer scaffolds were implanted into host animals, either in the 
omentum, the interscapular fat pad, or the mesentery. In three cases of fetal intestinal 
implantation coupled with partial hepatectomy successful engraftment occurred in the 
omentum, one forming a visible 6.0 mm cyst. Three cases of hepatocyte implantation, one 
using adult cells and two using fetal cells, also engrafted showing viability of hepatocytes, 
mitotic figures, and vascularization of the cell mass. We termed this concept “chimeric 
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neomorphogenesis.” Over time, it provided a major basis for what is now called Tissue 
Engineering.
In 1993, we wrote a paper in Science entitled “Tissue engineering” where we defined tissue 
engineering as “an interdisciplinary field that applies the principles of engineering and the 
life sciences toward the development of biological substitutes that restore, maintain, or 
improve tissue function” (see figure 1). This paper has been cited approximately 5200 times. 
Today tissue engineering is a thriving areas. As of 2011, there are over 100 companies 
involved in tissue engineering, employing 14,000 people and generating nearly $4 billion in 
sales [2]. Here we discuss some of the progress that’s been made and the challenges ahead.
Liver and Vital Organs
In our initial paper describing what is now known as tissue engineering, we presented data 
on cell-scaffolding implantation of liver, pancreas, and intestine. This work pointed to the 
hope of creating vital organs on demand to solve the organ shortage worldwide. Through the 
years since presentation at APSA in May, 1987, vital organ tissue engineering has continued 
to be a major focus of our laboratories with a major emphasis on liver fabrication. After the 
initial work which demonstrated proof of principle, studies were performed to increase 
implanted liver cell mass. The small bowel mesentery was used as a large vascularized 
tissue bed for the placement of the liver cell scaffolding between multiple mesenteric leaves. 
Hepatocytes were obtained by collagenase perfusion of livers of co-genic Wistar rats and 
were seeded onto non-woven filamentous sheets of polyglycolic acid 1x3 cm. in size, 2 mm 
in thickness, at density of 500,000 cells/cm2. They were implanted into 26 Gunn rats (UDP-
glucuronyl transferase deficient). Eight sheets per animal were implanted. Moderate 
inflammation, neovascularization, and the presence of hepatocytes were seen in 96% of 
animals. Conjugated bilirubin was identified in 46% of animals implanted with normal 
hepatocytes and none detected in animals implanted with deficient liver hepatocytes [3].
We then studied implantation in a large animal canine model of hyperuricosuria. The 
Dalmatian dog is known to have an inborn error of metabolism in the hepatocyte which 
causes a decrease in the degradation of uric acid into allantoin. This leads to a rise in uric 
acid levels in blood and urine. Four male Dalmatian dogs were used as recipients of normal 
hepatocytes. Poly vinyl alcohol sponges measuring 250 cm.2×5 mm were implanted 
between the leaves of mesentery and 1.5×10(10) normal hepatocytes from donor beagles 
were implanted into prevascularized sponges after a portacaval shunt had been created for 
hepatotrophic stimulation. Excretion of uric acid decreased from 136.3 to 44.1 
micromol/kg/day from week 2 to week 6. Control animals remained unchanged [4].
Although these results were promising, we concluded that the results were not adequate to 
produce a device for human testing. These approaches all relied on angiogenesis to form 
permanent vascularized new tissue and surviving, functioning cell mass was not sufficiently 
safe. Consequently, we developed a new approach in 1998 in which the vascular supply was 
designed and engineered as part of the cell scaffold implant. Using standard 
photolithography techniques (figure 2), trench patterns reminiscent of the branched 
architecture of vascular and capillary networks were etched onto silicon and Pyrex surfaces 
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to serve as templates. Hepatocytes and endothelial cells were cultured and subsequently 
lifted as single cell monolayers from these two dimensional molds. Both cell types were 
viable and proliferative on these surfaces. In addition, the hepatocytes maintained albumin 
production. The lifted monolayers were then folded into compact 3 dimensional tissues 
thereby demonstrated a new approach to large scale new tissue production (figure 3) [5].
In 1997, we described the use of a novel 3 D printer prototype to fabricate complex 
scaffolding for tissue engineering directly in three dimensions on the scale of hundreds of 
microns [6]. Since that publication, the technology has advanced to where extreme 
resolution approaching 25 microns can be achieved. Over the past several years, bioprinting 
of cells in hydrogels has emerged as a new tool for the field [7]. Organ decellularization in 
which biological scaffolding can be created by detergent washing of liver and other organs 
is now being developed to provide scaffolding which can be recellularized with organ 
specific cells as well as the cells of the vascular circulation since the vascular architecture is 
also preserved [8].
Spinal cord
Each year approximately 10,000 Americans sustain spinal cord injuries (SCI). Functional 
deficits following SCI result from damage to or severance of axons, loss of neurons and glia, 
and demyelination. SCI pathology is determined not only by the initial mechanical insult, 
but also by secondary processes including ischemia, anoxia, free-radical formation, and 
excitotoxicity that occur over hours and days following injury [9]. We sought to develop a 
tissue engineering approach that simulated the architecture of the healthy spinal cord 
through an implant consisting of a polymer scaffold seeded with neural stem cells (NSCs) 
modeled after the gray and white matter of the intact cord. The scaffold’s inner portion 
would stimulate the gray matter via a porous polymer layer designed to be seeded with 
NSCs [10] for cellular replacement as well as trophic support. The outer portion would 
stimulate the white matter with long, axially oriented pores for axonal guidance and radial 
porosity to allow fluid transport while inhibiting ingrowth of scar tissue. The scaffold is 
designed to be tailored to fit into a variety of cavities. In our initial study, the scaffold was 
tailored to fit into the cavity created by a midline lateral hemisection in the spinal cord of an 
adult rat.
In a 50 animal study, implantation of the scaffold–neural stem cells unit into an adult rat 
hemisection model of SCI promoted long-term improvement in function (persistent for 1 
year in some animals) relative to a lesion-control group. At 70 days post injury, animals 
implanted with scaffold-plus-cells exhibited coordinated, weight-bearing hind limb stepping. 
Histology and immunocytochemical analysis suggested that this recovery might be 
attributable partly to a reduction in tissue loss from secondary injury processes as well as in 
diminished glial scarring. Tract tracing demonstrated corticospinal tract fibers passing 
through the injury epicenter to the caudal cord, a phenomenon not present in untreated 
groups. Increased local GAP-43 expression was not seen in treated animals and these results 
suggest a possible regeneration component [11].
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While rodent models exhibit high degrees of spontaneous recovery from SCI injury, animal 
care concerns preclude complete cord transections in non-human primates and other larger 
vertebrate models. To overcome such limitations a segmental thoracic (T9–T10) spinal cord 
hemisection was created and characterized in the African green monkey. Physiological 
tolerance of the model permitted behavioral analyses for a prolonged period post-injury, 
extending to predefined study termination points at which histological and 
immunohistochemical analyses were performed. Four monkeys were evaluated (one 
receiving no implant at the lesion site, one receiving a poly(lactide-co-glycolide) (PLGA) 
scaffold, and two receiving PLGA scaffolds seeded with human neural stem cells (hNSC)). 
All subjects exhibited Brown-Séquard syndrome 2 days post-injury consisting of ipsilateral 
hind limb paralysis and contralateral hind limb hypesthesia with preservation of bowel and 
bladder function. A 20-point observational behavioral scoring system allowed quantitative 
characterization of the levels of functional recovery. Histological endpoints including silver 
degenerative staining and Iba1 immunohistochemistry for microglial and macrophage 
activation, were determined to reliably define lesion extent and correlate with 
neurobehavioral data. These studies also showed efficacy and safety similar to the rat studies 
[12]. Most recently, this procedure was approved for human testing. At this time, the first 2 
patients have been treated with no negative consequences and with initial promising results.
Blood vessels
We developed techniques to produce small-caliber autologous arteries in vitro from vascular 
cells grown on a biodegradable polymer matrix, by means of a pulsatile perfusion system for 
vessel culture. Ideal biological grafts should possess a confluent endothelium and 
differentiated, quiescent, smooth muscle cells (SMCs), as well as sufficient mechanical 
integrity and elastic moduli to allow suture retention and tolerance of systemic arterial 
pressures. Because vascular cells are exposed to pulsatile physical forces during most of 
vasculogenesis [13] and throughout life, we hypothesized that the development of arteries in 
the laboratory would be facilitated by the application of pulsatile physical stress to cultured 
vascular cells [14].
The biomimetic system we developed for vessel culture is composed of bioreactors 
containing engineered vessels assembled in a parallel flow system. In initial experiments, a 
suspension of cultured SMCs isolated from the medial layer of bovine aorta [15] was 
pipetted onto tubular biodegradable polyglycolic acid (PGA) scaffolds that were secured in 
reactors [16]. The surface of the PGA scaffolds was chemically modified [17] to increase 
hydrophilicity, increase adsorption of serum proteins, and improve SMC attachment. After 
an initial SMC seeding period of 30 min, the bioreactors were filled with medium and the 
SMCs were cultured under conditions of pulsatile radial stress for 8 weeks. Control vessels 
were cultured without pulsatile radial stress under otherwise identical conditions.
To assess the practical utility of these cultured arteries in vivo, we undertook initial 
implantation studies in miniature swine. Autologous arterial SMCs and ECs were cultured 
for each 6-month-old animal from small biopsies of the common carotid artery. In vitro graft 
controls were done without pulsatile flow. All animals underwent implantation into the right 
saphenous artery, which is a branch of the femoral artery and is the largest artery in the 
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distal half of the hind limb. Animals were followed for up to 4 weeks, after which time the 
grafts were explanted for assessment of histology and contractile function postoperatively as 
assessed by Doppler. A pulsed xenograft vessel was examined by digital subtraction 
angiography at 24 days after implantation and was patent, without evidence of stenosis or 
dilatation. The xenograft also had unchanged contractile responses to prostaglandin F2α 
when explanted at 4 weeks. A pulsed autologous graft remained open for 4 weeks as 
assessed by Doppler [14]. This general approach is now being tested in humans using 
decellularized systems with initial promising results.
We developed the first approached for controlling the differentiation of human embryonic 
stem cells into vascular endothelial cells [18].
Additional areas
In other studies, we engineered cartilage, heart valves, bone, intestine, urological structures, 
tendons, and muscle. This work has also helped lead to the creation in humans of skin [19] 
now approved for burn victims and patients with diabetic skin ulcers (e.g., marketed by 
Shire), urinary bladder [20] and cartilage. Already over a million patients have received 
tissue engineered human skin (for burns or diabetic skin ulcers) based on our discoveries 
(e.g., Dermagraft, uses the exact polymer we originally used, polylactic glycolic acid, in this 
case with neonatal fibroblasts).
Coupled with these discoveries of the necessary biological principles of tissue formation, we 
developed new chemical approaches to produce scaffolding materials, which would 
specifically signal genetic cellular events including proliferation, provide attachment 
sequences for the cells, as well as augment angiogenesis, all in harmony to produce normal 
tissue [21]. We also created new biodegradable materials to further advance scaffolding 
technology for tissue engineering [22]. Other contributions include the first methods to 
create materials for controlling stem cell differentiation [23], methods of using stem cells to 
create muscle [24], methods of using materials to create heart tissue [25], and synthesizing 
the first surfaces for growing stem or iPS cells in a completely xenofree, serum free 
environment [26].
The future
This brief summary only touches on the progress that has been made since 1987 in the fields 
of tissue engineering and regenerative medicine. Almost every tissue of the human body has 
been studied for the possibility of replacement with living tissue engineered structures. 
Every year more clinical trials are showing success leading to clinical application. Progress 
will continue with collaborative approaches among clinicians, scientists and engineers.
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Photolithographic approach to create a vascular bed for tissue engineered liver.
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A tiled lobular architecture of a vascular bed micro machined for tissue engineered liver.
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